Cargando…

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy

The importance of serum immunoglobulin (Ig)G concentration in IgG replacement therapy for primary immunodeficiency diseases is established in certain settings. Generally, IgG is infused via the intravenous (IVIG) or subcutaneous (SCIG) route. For IVIG infusion, published data demonstrate that higher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orange, J S, Belohradsky, B H, Berger, M, Borte, M, Hagan, J, Jolles, S, Wasserman, R L, Baggish, J S, Saunders, R, Grimbacher, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Science Inc 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406377/ https://www.ncbi.nlm.nih.gov/pubmed/22774992 http://dx.doi.org/10.1111/j.1365-2249.2012.04594.x

Ejemplares similares

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency
por: Hoffmann, F, et al.
Publicado: (2010)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2017)

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2018)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program
por: Zhu, Julia, et al.
Publicado: (2019)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency
por: Haddad, Elie, et al.
Publicado: (2011)

Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations
por: Wasserman, Richard L.
Publicado: (2008)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis
por: Dimou, Maria, et al.
Publicado: (2023)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
por: Chouksey, Akhilesh, et al.
Publicado: (2005)

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis
por: Patrick, Cherin, et al.
Publicado: (2014)

Subcutaneous immunoglobulin replacement therapy in a heart transplant recipient with severe recurrent infections
por: Carbone, Javier, et al.
Publicado: (2015)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia
por: Mustafa, S. Shahzad, et al.
Publicado: (2021)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
por: Borte, M., et al.
Publicado: (2016)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
por: Cherin, Patrick, et al.
Publicado: (2015)

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
por: Grigoriadou, S, et al.
Publicado: (2022)

Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report
por: Streu, Erin, et al.
Publicado: (2020)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency
por: Berger, Melvin
Publicado: (2008)

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age
por: Patel, Niraj C., et al.
Publicado: (2015)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

Fatigue Is Common in Immunoglobulin G Subclass Deficiency and Correlates With Inflammatory Response and Need for Immunoglobulin Replacement Therapy
por: Wågström, Per, et al.
Publicado: (2022)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nb12vfsipf3h1o6gm4t8dq4klv